[REVISION HISTORY]

Advances and challenges in mRNA and immunotherapy trials

10 recorded revisions of this situation.

What changed

2026-10-25 12:56 UTC → 2026-10-25 13:43 UTC · added ~~removed~~

Cancer immunotherapy is evolving through personalized mRNA vaccines and cellular therapies. Recent breakthroughs include a platform generating T-cells from hematopoietic stem cells, which offers a ready-to-use alternative to traditional, costly methods of extracting and modifying a patient’s own cells. This approach has shown promise in targeting lung and ovarian tumors with superior persistence. In the mRNA sector, Moderna’s personalized vaccine, intismeran, has reached significant milestones. Results from the Phase III INTerpath-001 clinical trial involving 1,137 patients with high-risk melanoma show that combining the vaccine with the immunotherapy drug Keytruda significantly reduces the risk of recurrence or death. Specifically, 82.2% of patients in the combination group remained recurrence-free after a median follow-up of 24.6 months, compared to 70.0% in the group receiving Keytruda alone. The data also indicates a 38% reduction in the risk of cancer spread. The vaccine is custom-designed for each patient by targeting neoantigens—proteins resulting from specific genetic mutations within an individual's tumor—and involves a regimen of nine doses administered at three-week intervals. While medical ~~experts~~ experts, including researchers from MD Anderson Cancer Center, have hailed these results as a “significant breakthrough,” the stock market reaction was mixed. Following the detailed presentation of the data, Moderna shares experienced a significant decline, dropping as much as 25% to approximately $181, despite previous surges based on earlier, less detailed reports. Other developments include positive early results for a breast cancer vaccine at the Cleveland Clinic and a study in the Netherlands where immunotherapy supplemented traditional methods for colorectal cancer, resulting in no recorded recurrences within five years. Despite this progress, the field faces hurdles, including medical disinformation and the complex clinical challenge of transitioning from infectious disease vaccine success to oncology.

Versions

Select a version to see what changed compared to the one before it.